Abnormal recall rate, false positive rate, benign biopsy rate (per 1000 screens), positive predictive value (PPV) by service provider group, region and study period. Number in parenthesis is the corresponding 95% CI
| Region | Study period | Abnormal recall rate (%) | False positive rate (%) | Benign biopsy rate (per 1000 screens) | Positive predictive value (%) | ||||||||
| CC | Screen test | Rate ratio* | CC | Screen test | Rate ratio | CC | Screen test | Rate ratio | CC | Screen test | OR* | ||
| Edmonton area | A | 9.7 | 4.1 | 2.35 | 9.4 | 3.7 | 2.51 | 8.7 | 6.2 | 1.38 | 3.3 | 9.9 | 0.30 |
| (9.5 to 9.9) | (3.7 to 4.6) | (2.1 to 2.62) | (9.2 to 9.6) | (3.3 to 4.2) | (2.24 to 2.82) | (8.0 to 9.4) | (4.6 to 8.3) | (1.03 to 1.85) | (2.8 to 3.7) | (6.9 to 13.7) | (0.2 to 0.44) | ||
| B | 8.6 | 3.5 | 2.29 | 8.3 | 3.1 | 2.50 | 6.9 | 4.3 | 1.62 | 3.4 | 11.8 | 0.30 | |
| (8.4 to 8.8) | (3.1 to 4.0) | (2.01 to 2.62) | (8.1 to 8.5) | (2.7 to 3.6) | (2.17 to 2.88) | (6.3 to 7.5) | (2.8 to 6.4) | (1.08 to 2.43) | (3.0 to 3.9) | (7.7 to 17.0) | (0.19 to 0.48) | ||
| Calgary area | A | 11.2 | 3.5 | 3.11 | 10.8 | 3.0 | 3.49 | 8.9 | 4.6 | 1.90 | 3.5 | 14.5 | 0.21 |
| (10.9 to 11.4) | (3.1 to 3.9) | (2.76 to 3.49) | (10.5 to 11.0) | (2.6 to 3.4) | (3.08 to 3.96) | (8.2 to 9.7) | (4.2 to 6.3) | (1.35 to 2.65) | (3.1 to 4.0) | (10.6 to 19.3) | (0.15 to 0.3) | ||
| B | 8.6 | 3.2 | 2.55 | 8.3 | 2.6 | 2.98 | 6.6 | 4.2 | 1.48 | 3.8 | 17.9 | 0.21 | |
| (8.4 to 8.9) | (2.7 to 3.7) | (2.21 to 2.95) | (8.1 to 8.5) | (2.2 to 3.1) | (2.53 to 3.49) | (6.0 to 7.2) | (2.7 to 6.4) | (0.97 to 2.24) | (3.4 to 4.3) | (12.5 to 24.5) | (0.14 to 0.31) | ||
| Other areas | A | 5.9 | 3.9 | 1.53 | 5.6 | 3.4 | 1.62 | 6.6 | 5.9 | 1.09 | 5.9 | 11.7 | 0.46 |
| (5.7 to 6.2) | (3.5 to 4.2) | (1.38 to 1.69) | (5.3 to 5.9) | (3.1 to 3.7) | (1.46 to 1.81) | (5.7 to 7.7) | (4.6 to 7.5) | (0.83 to 1.43) | (4.7 to 7.2) | (8.9 to 15.0) | (0.32 to 0.65) | ||
| B | 8.1 | 3.7 | 2.12 | 7.7 | 3.2 | 2.35 | 6.6 | 5.2 | 1.16 | 4.1 | 13.6 | 0.28 | |
| (7.8 to 8.4) | (3.4 to 4.1) | (1.91 to 2.35) | (7.4 to 8.0) | (2.9 to 3.6) | (2.1 to 2.62) | (5.8 to 7.5) | (4.0 to 6.8) | (0.87 to 1.55) | (3.4 to 5.0) | (10.4 to 17.4) | (0.2 to 0.39) | ||
| Total | A | 9.7 | 3.8 | 2.50 | 9.4 | 3.4 | 2.72 | 8.5 | 5.6 | 1.47 | 3.7 | 11.9 | 0.27 |
| (9.6 to 9.9) | (3.6 to 4.1) | (2.35 to 2.65) | (9.2 to 9.5) | (3.2 to 3.6) | (2.55 to 2.9) | (8.0 to 8.9) | (4.8 to 6.6) | (1.25 to 1.74) | (3.4 to 4.0) | (10.0 to 14.0) | (0.22 to 0.34) | ||
| B | 8.5 | 3.5 | 2.29 | 8.2 | 3.0 | 2.56 | 6.7 | 4.8 | 1.35 | 3.7 | 14.1 | 0.26 | |
| (8.4 to 8.6) | (3.3 to 3.8) | (2.14 to 2.46) | (8.1 to 8.3) | (2.8 to 3.3) | (2.38 to 2.76) | (6.4 to 7.1) | (3.9 to 5.8) | (1.11 to 1.65) | (3.4 to 4.0) | (11.7 to 16.8) | (0.21 to 0.32) | ||
*PPV was examined using a logistic regression model because the log-binomial model did not converge.
CC, community clinics.